A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02000947. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Study identification
- NCT ID
- NCT02000947
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 459 participants
Conditions and interventions
Conditions
Interventions
- MEDI4736 Drug
- tremelimumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 101 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 24, 2013
- Primary completion
- Sep 16, 2019
- Completion
- Sep 16, 2019
- Last update posted
- Oct 30, 2019
2013 – 2019
United States locations
- U.S. sites
- 28
- U.S. states
- 21
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35294-3300 | — |
| Research Site | Tucson | Arizona | 85715 | — |
| Research Site | Los Angeles | California | 90025 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | San Francisco | California | 94158 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | New Haven | Connecticut | 06510 | — |
| Research Site | Newark | Delaware | 19713 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Baltimore | Maryland | 21287 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Lebanon | New Hampshire | 03756 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Huntersville | North Carolina | 28078 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Portland | Oregon | 97213 | — |
| Research Site | Fort Worth | Texas | 76104 | — |
| Research Site | Houston | Texas | 77521 | — |
| Research Site | Tyler | Texas | 75702 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Seattle | Washington | 98109 | — |
| Research Site | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02000947, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2019 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02000947 live on ClinicalTrials.gov.